Prof. Malú Martínez-Chantar was our last guest. She is an experienced liver biology and disease researcher with a strong publication record in top journals. She has received continuous support from national and international public and private funding, including the NIH. Prof. Martinez-Chantar coordinates the Translational Area at the National Institute for the Study of Liver & Gastrointestinal Diseases and is involved in the Scientific Advisory Boards of national and international centers. She actively participates in various networks such as CibereHD, Women in Hepatology: International Consortium, Hepamet Registry, MetaboCancer Excellence Network, and EU COST actions. Professor Martinez-Chantar’s collaborative efforts with pharmaceutical companies have culminated in numerous patent applications and the successful licensing of products. In a recent entrepreneurial endeavor, she established a spin-off company, Gibela Therapeutics, based in Basel, Switzerland, with a focus on advancing treatments for liver diseases. This presentation unfolds at the intersection of pioneering research and innovative solutions in hepatic diseases. «Translational Basic Research: Navigating Opportunities and Challenges in the Development of Therapeutic RNA Molecules for Addressing Hepatic Diseases via Magnesium Homeostasis» explores a transformative approach to hepatic conditions by leveraging the nuanced dynamics of magnesium homeostasis.
The session aims to navigate through the promising opportunities that therapeutic RNA molecules present in reshaping the landscape of hepatic diseases. By delving into the profound impact of magnesium homeostasis, attendees will gain insights into the pivotal role it plays in the development and application of therapeutic interventions. Together, we aspire to pave the way for groundbreaking advancements in hepatic healthcare.
Sarp Uzun was born in Adana, Turkey. He graduated from Hacettepe University Faculty of Medicine in 2020 in Ankara, Turkey. In 2016, he enrolled in the MD-PhD program at the same university and received his PhD degree in 2021 from the Tumor Biology and Immunology Ph.D. program. During his PhD, he worked on β-Catenin N-terminal region alterations in neoplastic diseases. He joined the lab of PD.Dr. Matthias Matter at the Institute of Pathology, University Hospital Basel in August 2021. Currently, he is working on molecular and morphological analysis of immune-mediated liver diseases, primarily SARS-CoV-2 vaccine-induced liver injury and checkpoint-inhibitor-induced liver injury.
Our first speaker was Prof Jonathan Fallowfield, personal chair of Translational Liver Research at the University of Edinburgh and Honorary Consultant Hepatologist at the Royal Infirmary of Edinburgh (UK).
Professor Jonathan Fallowfield’s research interests span basic science and translational/clinical studies in hepatology. Key topics include mechanisms of liver fibrogenesis and fibrosis regression; portal hypertension and hepatorenal syndrome; biomarkers (particularly imaging); and discovery/development of novel therapies for liver fibrosis, NASH and portal hypertension.
4th Swiss Autoimmune Liver Disease Meeting in Lugano, Switzerland, September 21-22, 2023
Fondazione Epatocentro Ticino hosts its 4th Swiss Autoimmune Liver Disease Meeting in Lugano, Switzerland, on September 21-22, 2023.
The conference is bringing together world’s top experts in the field of autoimmune liver diseases in collaboration with members of the EASL DHILI Consortium). Learn more about speakers and program here.
EASL DHILI Consortium meeting @EASL Liver Congress 2023. Vienna, Austria. 21-24 June 2023.
Our first official meeting took place during the EASL Congress in Vienna on June 23rd 2023 between 11.00 and 12.00 pm (CEST time) in the Schubert room 4.
The main objective was to discuss opportunities this consortium brings and set goals for the next 6 months.
Drug-Induced Liver Injury (DILI) Diagnosis: More Than Guilt by Association
19 June 2023
The webinar has been focused on the identification, diagnosis of drug, and herb-induced liver injury. Each topic has been chosen based on a key publication that addresses an important challenge in drug-induced liver injury.
Las XXII Jornadas de Avances en Hepatología se celebrarón los pasados días 18 y 19 de Mayo de 2023 en el Aula Magna de la Facultad de Medicina de la Universidad de Málaga.
Durante estas jornadas se discutieron numerosos temas de actualidad e interés en Hepatología impartidos por profesionales con reconocimiento internacional en la materia. Estas jornadas brindaron posibilidades de encuentro y establecimiento de colaboración en una atmosfera distendida y cordial y en un marco privilegiado, que es el que ofrece nuestra ciudad particularmente en esta época del año. Las Jornadas de Hepatología de Málaga son ya un curso de referencia en el panorama nacional.
El programa se estructuró en torno a 6 mesas redondas, una charla-coloquio y una conferencia de clausura impartida por el Dr. Pere Ginés, del Hospital Clínic de Barcelona; experto mundial en enfermedades hepáticas y en particular cirrosis hepática.
Además, el curso está acreditado por la Dirección General de Investigación y Gestión del Conocimiento de la Consejería de Salud de la Junta de Andalucia. También tiene el reconomiento de interés sanitario-científico por la Junta de Andalucía. También tiene validez como Actividad Formativa de Doctorado, 1 crédito (25 horas). Programa Doctorado BIOMEDICINA, INVESTIGACIÓN TRASLACIONAL Y NUEVAS TECNOLOGÍAS EN SALUD, Facultad de Medicina, Universidad de Málaga.
Sede: Aula Magna, Facultad de Medicina, Universidad de Málaga (Boulevard Louis Pasteur, 32. Campus de Teatinos, S/N, 29010 Málaga)
Organizadores: Dpto de medicina y Unidad de Gestión Clínica de Digestivo; Instituto de Investigación Biomédica de Málaga (IBIMA); Hospital Universitario Virgen de la Victoria. Facultad de Medicina, Universidad de Málaga; Prospective European Drug-Induced Liver Injury.